



**ESPS PEER REVIEW REPORT**

**Name of journal:** World Journal of Hepatology

**ESPS manuscript NO:** 13503

**Title:** Chemotherapy and target therapy of hepatocellular carcinoma: New advances and challenges to us

**Reviewer code:** 00289387

**Science editor:** Yue-Li Tian

**Date sent for review:** 2014-08-26 17:19

**Date reviewed:** 2014-09-09 20:39

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

**COMMENTS TO AUTHORS**

The authors reviewed a large body of chemotherapeutic drugs currently used or tested in advanced hepatocarcinomas (HCC), particularly in cancer angiogenesis including sorafenib, sunitinib, brivanib, bevacizumab etc. A few weaknesses are present in the current version, which needs significant work to improve. 1) The present version of this paper is too long, as this reviewer feels the description of each agent is identical in a total of more than 10 drugs. To keep attracting readers' interests, it is highly recommended to make a concise version in which some of agents that lack noticeable tolerance and improvement of patients' survival (OS, PFS) should be eliminated or briefly mentioned. In addition, most of the side effects should be removed because they are almost same. 2) A number of typos including grammatical errors and incorrect spellings throughout the entire manuscript need to be corrected (e.g. in Abstract). The title of this paper needs improvement such as a removal of "to us". The Abstract also requires rewriting because it contains redundant information/description and it should present extremely clear, important, and succinct info. 3) Are there any reports that showed pathological changes in some of clinical trials? If tumor stages, size, and metastasis status are available, please provide them. Such information will help demonstrate therapeutic efficacy. 4) For so many diversified agents available, are there any indications of HCC patients specific for an optimal selection of some anti-angiogenic drugs or just a random selection for treatment, because some of these agents appear to have similar targets such as VEGFR and/or



## BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

---

PDGFR? 5) Provide full names of OS, PFS, TTP as they appeared at the first time in the text.



## BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

### ESPS PEER REVIEW REPORT

**Name of journal:** World Journal of Hepatology

**ESPS manuscript NO:** 13503

**Title:** Chemotherapy and target therapy of hepatocellular carcinoma: New advances and challenges to us

**Reviewer code:** 02861333

**Science editor:** Yue-Li Tian

**Date sent for review:** 2014-08-26 17:19

**Date reviewed:** 2014-09-11 16:26

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Existing	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

#### COMMENTS TO AUTHORS

This review study summarized the chemotherapy and target therapy of hepatocellular carcinoma during the past decade.